Evaluation Of The Effectiveness And Safety Of Disitamab Vedotin For HER2-Expressing Recurrent Cervical Cancer After Progression On Platinum-Based Treatment-A Single-Arm, Multicenter, Open-Label, Phase II Clinical Study
ESGO eAcademy, Jinwei Miao,
410983
Efficacy And Safety Of Iparomlimab And Tuvonralimab In Previously Treated Patients With Recurrent Or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase 2 Clinical Trial (DUBHE-C-206)
ESGO eAcademy, Jihong Liu,
410982
TROPHIMMUN, Cohort A: Maintained Benefit From Second-Line Avelumab After Failure To Monochemotherapy In Low-Risk Gestational Trophoblastic Tumor, With A 4 Year-Follow-Up.
ESGO eAcademy, Pierre-Adrien Bolze,
410946
InnovaTV 301/ENGOT-Cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study Of Tisotumab Vedotin Versus Investigator’s Choice Of Chemotherapy In 2L Or 3L Recurrent Or Metastatic Cervical Cancer
ESGO eAcademy, Antonio Gonzalez-Martin,
410929